Evaluate the Effect of Genasense on the Efficacy/Safety of Rituximab/Fludarabine Treatment in Untreated Subjects With Chronic Lymphocyctic Leukemia
Showing 1 - 25 of >10,000
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial (Nemtabrutinib, Fludarabine, Cyclophosphamide)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Leukemia
- Nemtabrutinib
- +7 more
- (no location specified)
Nov 30, 2022
Untreated Chronic Lymphocytic Leukemia Trial in Worldwide (Acalabrutinib, Rituximab, Chlorambucil)
Recruiting
- Untreated Chronic Lymphocytic Leukemia
- Acalabrutinib
- +2 more
-
Beijing, China
- +50 more
Sep 26, 2022
Chronic Lymphocytic Leukemia (CLL) Trial in Worldwide (Obinutuzumab, Venetoclax, Fludarabine)
Recruiting
- Chronic Lymphocytic Leukemia (CLL)
- Obinutuzumab
- +5 more
-
Aurora, Colorado
- +55 more
Jan 30, 2023
Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in United States (drug, other, biological)
Active, not recruiting
- Anemia
- +2 more
- Cyclophosphamide
- +6 more
-
Birmingham, Alabama
- +795 more
Jan 28, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed Trial in Tianjin (Zanubrutinib, Fludarabine,
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
- Zanubrutinib, bendamustine, rituximab
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Mar 18, 2022
Chronic Lymphocytic Leukemia Trial in Worldwide (Acalabrutinib, Venetoclax, Chemoimmunotherapy)
Recruiting
- Chronic Lymphocytic Leukemia
- Acalabrutinib
- +3 more
-
Fountain Valley, California
- +201 more
Jan 16, 2023
Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)
Recruiting
- Acute Lymphoblastic Leukemia
- +2 more
- allogenic CD19-CAR-NK cells
-
Xuzhou, Jiangsu, ChinaThe Affiliated Hospital of Xuzhou Medical University
Feb 11, 2023
Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia Trial in Tianjin (LILRB4 STAR-T cells injection)
Not yet recruiting
- Acute Myelogenous Leukemia
- Chronic Myelomonocytic Leukemia
- LILRB4 STAR-T cells injection
-
Tianjin, Tianjin, China
- +1 more
Feb 12, 2023
Chronic Lymphocytic Leukemia, Leukemia Trial in United States (Ibrutinib, Fludarabine, Cyclophosphamide)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Leukemia
- Ibrutinib
- +3 more
-
Coral Gables, Florida
- +8 more
Sep 28, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in China (ICP-022, Chlorambucil, Rituximab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- ICP-022
- +2 more
-
Bengbu, Anhui, China
- +55 more
Mar 25, 2022
B-cell Lymphoma, B-cell Acute Lymphoblastic Leukemia Trial in Hangzhou (QN-019a, Rituximab, Cyclophosphamid)
Recruiting
- B-cell Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- QN-019a
- +4 more
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Medical College of Zhejiang Uni
May 17, 2022
Chronic Lymphocytic Leukemia Trial (Acalabrutinib, Obinutuzumab)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- (no location specified)
Jul 10, 2023
Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia Trial in
Active, not recruiting
- Stage I Chronic Lymphocytic Leukemia
- +3 more
- Cyclophosphamide
- +4 more
-
Scottsdale, Arizona
- +363 more
Dec 30, 2022
Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)
Completed
- Lymphoid Leukemia
- +2 more
- Bendamustine
- +2 more
-
Madison, WisconsinUniversity of Wisconsin
Jan 30, 2023
Chronic Lymphocytic Leukemia Trial in San Diego (ISF35)
Completed
- Chronic Lymphocytic Leukemia
- ISF35
-
San Diego, CaliforniaUniversity of California, San Diego Moores Cancer Center
Sep 15, 2021
Chronic Lymphocytic Leukemia Trial in Boston (IPI-145, Fludarabine, Cyclophosphamide)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- IPI-145
- +3 more
-
Boston, Massachusetts
- +1 more
Mar 10, 2022
Relapsed DLBCL, Refractory DLBCL Trial in Hackensack (ABT-199, Ibrutinib, Rituximab)
Active, not recruiting
- Relapsed Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- ABT-199
- +2 more
-
Hackensack, New JerseyJohn Theurer Cancer Center at Hackensack University Medical Cent
Oct 7, 2022
Chronic Lymphocytic Leukemia Trial in Cologne (Ibrutinib, Placebo)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib
- Placebo
-
Cologne, GermanyGerman CLL Study Group
Dec 16, 2021
B-cell Acute Lymphoblastic Leukemia, B-Cell Lymphoma, Unspecified Trial in Guangzhou, Guanzhou (CD19 CAR T-Cell(CAT19T2))
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- B-Cell Lymphoma, Unspecified
- CD19 CAR T-Cell(CAT19T2)
-
Guangzhou, Guangdong, China
- +1 more
Nov 4, 2022
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic
Active, not recruiting
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +6 more
- Dexamethasone
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 2, 2022
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Fairway, Houston (SC291)
Recruiting
- Non Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
-
Fairway, Kansas
- +1 more
May 30, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia Trial in Columbus (acalabrutinib,
Active, not recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- acalabrutinib
- +3 more
-
Columbus, OhioResearch Site
Mar 11, 2022
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)
Recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Rituximab
- Zanubrutinib
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022